Rankings
▼
Calendar
JAZZ Q2 2022 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q2 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$933M
+24.1% YoY
Gross Profit
$809M
86.7% margin
Operating Income
$86M
9.2% margin
Net Income
$35M
3.7% margin
EPS (Diluted)
$0.55
QoQ Revenue Growth
+14.6%
Cash Flow
Operating Cash Flow
$303M
Free Cash Flow
$291M
Stock-Based Comp.
$54M
Balance Sheet
Total Assets
$11.2B
Total Liabilities
$8.0B
Stockholders' Equity
$3.2B
Cash & Equivalents
$711M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$933M
$752M
+24.1%
Gross Profit
$809M
$633M
+27.8%
Operating Income
$86M
-$70M
+222.9%
Net Income
$35M
-$363M
+109.5%
Revenue Segments
Xyrem
$269M
29%
Xywav
$235M
26%
Epidiolex/Epidyolex
$175M
19%
Rylaze/Enrylaze
$73M
8%
Zepzelca
$68M
7%
Defitelio/Defibrotide
$55M
6%
Vyxeos
$34M
4%
Sativex
$4M
0%
Other Products
$2M
0%
Geographic Segments
UNITED STATES
$858M
92%
Europe
$61M
7%
Other Countries
$14M
1%
← FY 2022
All Quarters
Q3 2022 →